Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Byrne

B.J.

, Falk

D.J.

, Pacak

C.A.

et al. 2011. Pompe disease gene therapy. Hum. Mol. Genet., 20:R61–R68.

Friedmann

, Rabin

, Frankel

M.S.

2010. Ethics: Gene doping and sport. Science, 327:647–648.

Harridge

S.D.

, Velloso

C.P.

2009. IGF-I and GH: Potential use in gene doping. Growth Horm. IGF Res., 19:378–382.

Macedo

, Moriggi

, Vasso

et al. 2012. Enhanced athletic performance upon multi-site AAV-IGF1 gene transfer coincides with massive modification of the muscle proteome. Hum. Gene Ther., 23:146–157.

Mendell

J.R.

, Rodino-Klapac

L.R.

, Malik

2010a. Molecular therapeutic strategies targeting Duchenne muscular dystrophy. J. Child. Neurol., 25:1145–1148.

Mendell

J.R.

, Rodino-Klapac

L.R.

, Rosales

X.Q.

et al. 2010b. Sustained α-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol, 68:629–638.

, Le Guiner

, Gernoux

et al. 2011. Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: Implications for gene doping. Gene Ther., 18:709–718.

Sweeney

H.L.

2004. Gene doping. Sci. Am., 291:62–69.

A New Approach to Winning: Insulin-Like Growth Factor-I Signaling in Competitive Sport

Abstract

Get full access to this article

References